Why Science? | ICH Q11 Drug Substance Development, Manufacture and Control Strategy

The guidance describes approaches for developing and understanding manufacture of chemical entities and biotechnological or biological drug substances. It links scientific development with the information placed in CTD sections 3.2.S.2.2 through 3.2.S.2.6.

The scientific value of q11 focuses on drug-substance process understanding comes from linking knowledge to a controlled decision. The guidance describes approaches for developing and understanding manufacture of chemical entities and biotechnological or biological drug substances. It links scientific development with the information placed in CTD sections 3.2.S.2.2 through 3.2.S.2.6. Keep this boundary visible: A supplier’s commercial material is not automatically an acceptable regulatory starting material.

A strong science note separates observation from interpretation. Trace the main molecule and every important impurity through q11 focuses on drug-substance process understanding. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Next chapter

FDA lists Q11 as final guidance issued by CDER and CBER. The FDA page also links the February 2018 questions and answers that clarify starting-material selection and related implementation issues.

For the november 2012 q11 guidance is final, a useful model explains both the expected process and the response to variation. FDA lists Q11 as final guidance issued by CDER and CBER. The FDA page also links the February 2018 questions and answers that clarify starting-material selection and related implementation issues. Preserve this guardrail: Small-scale clearance may not represent commercial equipment without justification.

A strong science note separates observation from interpretation. Challenge the starting-material boundary for the november 2012 q11 guidance is final using the Q11 Q&A considerations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Physical, chemical, biological and microbiological attributes needed for the drug product guide process development. Structure, potency, purity, particle properties and stability may influence later formulation and clinical performance.

A trustworthy account of development begins with desired substance quality keeps evidence, assumptions and lifecycle action together. Physical, chemical, biological and microbiological attributes needed for the drug product guide process development. Structure, potency, purity, particle properties and stability may influence later formulation and clinical performance. Remember: A specification cannot replace understanding of an unstable or variable process.

A strong science note separates observation from interpretation. Compare development and commercial scale for development begins with desired substance quality using relevant engineering variables. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Reaction, fermentation, cell culture, harvest, purification, isolation, modification and storage steps are mapped with materials, outputs and hold points. This makes impurity creation, clearance and variability visible.

The scientific value of the process map should reveal transformations comes from linking knowledge to a controlled decision. Reaction, fermentation, cell culture, harvest, purification, isolation, modification and storage steps are mapped with materials, outputs and hold points. This makes impurity creation, clearance and variability visible. Keep this boundary visible: Chemical and biological manufacturing share principles but have different mechanisms and risks.

A strong science note separates observation from interpretation. Audit CTD consistency for the process map should reveal transformations across process, controls, validation and development sections. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

For chemical synthesis, the proposed starting material should have defined structure and properties and be justified in the context of the route. Enough upstream and downstream process must be described to control the drug substance.

For starting-material selection defines a regulatory boundary, a useful model explains both the expected process and the response to variation. For chemical synthesis, the proposed starting material should have defined structure and properties and be justified in the context of the route. Enough upstream and downstream process must be described to control the drug substance. Preserve this guardrail: A supplier’s commercial material is not automatically an acceptable regulatory starting material.

A strong science note separates observation from interpretation. Trace the main molecule and every important impurity through starting-material selection defines a regulatory boundary. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Transformations that create or change the impurity profile and upstream steps needed to control those impurities generally deserve regulatory visibility. Convenience or supplier designation alone is not a scientific justification.

A trustworthy account of impurity-forming steps influence what must be included keeps evidence, assumptions and lifecycle action together. Transformations that create or change the impurity profile and upstream steps needed to control those impurities generally deserve regulatory visibility. Convenience or supplier designation alone is not a scientific justification. Remember: Small-scale clearance may not represent commercial equipment without justification.

A strong science note separates observation from interpretation. Challenge the starting-material boundary for impurity-forming steps influence what must be included using the Q11 Q&A considerations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Knowledge of formation, reaction, solubility, purge and degradation supports where to prevent, monitor or test impurities. Mass balance and spiking or clearance studies can strengthen the explanation.

The scientific value of impurity fate links chemistry to control comes from linking knowledge to a controlled decision. Knowledge of formation, reaction, solubility, purge and degradation supports where to prevent, monitor or test impurities. Mass balance and spiking or clearance studies can strengthen the explanation. Keep this boundary visible: A specification cannot replace understanding of an unstable or variable process.

A strong science note separates observation from interpretation. Compare development and commercial scale for impurity fate links chemistry to control using relevant engineering variables. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Cell substrate, raw materials, culture conditions, harvest timing and purification can affect product-related variants, process-related impurities and biological activity. Control must account for living-system variability.

For biological processes have distinct sources of variability, a useful model explains both the expected process and the response to variation. Cell substrate, raw materials, culture conditions, harvest timing and purification can affect product-related variants, process-related impurities and biological activity. Control must account for living-system variability. Preserve this guardrail: Chemical and biological manufacturing share principles but have different mechanisms and risks.

A strong science note separates observation from interpretation. Audit CTD consistency for biological processes have distinct sources of variability across process, controls, validation and development sections. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Attributes that can affect quality should be linked to process steps and controls. Criticality can evolve as clinical knowledge, analytical capability and manufacturing experience improve.

A trustworthy account of critical quality attributes guide development keeps evidence, assumptions and lifecycle action together. Attributes that can affect quality should be linked to process steps and controls. Criticality can evolve as clinical knowledge, analytical capability and manufacturing experience improve. Remember: A supplier’s commercial material is not automatically an acceptable regulatory starting material.

A strong science note separates observation from interpretation. Trace the main molecule and every important impurity through critical quality attributes guide development. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Parameters are studied for their relationship to CQAs and process performance. Ranges should be justified with data, models or prior knowledge, and interactions should be considered where meaningful.

The scientific value of process parameters are evaluated through impact comes from linking knowledge to a controlled decision. Parameters are studied for their relationship to CQAs and process performance. Ranges should be justified with data, models or prior knowledge, and interactions should be considered where meaningful. Keep this boundary visible: Small-scale clearance may not represent commercial equipment without justification.

A strong science note separates observation from interpretation. Challenge the starting-material boundary for process parameters are evaluated through impact using the Q11 Q&A considerations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Mixing, transfer, residence time, oxygen, shear, chromatography loading and filtration can change with scale or equipment. Dimensionless relationships, small-scale models and confirmation runs can support transfer.

For scale-up requires engineering understanding, a useful model explains both the expected process and the response to variation. Mixing, transfer, residence time, oxygen, shear, chromatography loading and filtration can change with scale or equipment. Dimensionless relationships, small-scale models and confirmation runs can support transfer. Preserve this guardrail: A specification cannot replace understanding of an unstable or variable process.

A strong science note separates observation from interpretation. Compare development and commercial scale for scale-up requires engineering understanding using relevant engineering variables. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A multidimensional design space may be proposed when combinations of material attributes and parameters are demonstrated to assure quality. Boundaries, model uncertainty and scale relevance should be explicit.

A trustworthy account of design space can describe a robust operating region keeps evidence, assumptions and lifecycle action together. A multidimensional design space may be proposed when combinations of material attributes and parameters are demonstrated to assure quality. Boundaries, model uncertainty and scale relevance should be explicit. Remember: Chemical and biological manufacturing share principles but have different mechanisms and risks.

A strong science note separates observation from interpretation. Audit CTD consistency for design space can describe a robust operating region across process, controls, validation and development sections. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Controls may apply to starting materials, process steps, intermediates, hold times, facilities, in-process tests and final drug-substance specifications. The combination should manage variability and impurity risk.

The scientific value of the control strategy combines preventive and detective controls comes from linking knowledge to a controlled decision. Controls may apply to starting materials, process steps, intermediates, hold times, facilities, in-process tests and final drug-substance specifications. The combination should manage variability and impurity risk. Keep this boundary visible: A supplier’s commercial material is not automatically an acceptable regulatory starting material.

A strong science note separates observation from interpretation. Trace the main molecule and every important impurity through the control strategy combines preventive and detective controls. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Methods need suitable specificity, sensitivity and precision for development questions and release decisions. Orthogonal techniques can help characterise structure, variants or low-level impurities.

For analytical procedures support process knowledge, a useful model explains both the expected process and the response to variation. Methods need suitable specificity, sensitivity and precision for development questions and release decisions. Orthogonal techniques can help characterise structure, variants or low-level impurities. Preserve this guardrail: Small-scale clearance may not represent commercial equipment without justification.

A strong science note separates observation from interpretation. Challenge the starting-material boundary for analytical procedures support process knowledge using the Q11 Q&A considerations. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Commercial process performance is demonstrated under the applicable validation framework. Development knowledge supports the protocol, while continued monitoring checks that control persists after validation.

A trustworthy account of process validation confirms consistent performance keeps evidence, assumptions and lifecycle action together. Commercial process performance is demonstrated under the applicable validation framework. Development knowledge supports the protocol, while continued monitoring checks that control persists after validation. Remember: A specification cannot replace understanding of an unstable or variable process.

A strong science note separates observation from interpretation. Compare development and commercial scale for process validation confirms consistent performance using relevant engineering variables. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The process description, control of materials, critical steps and intermediates, process validation and development sections should agree. Cross-references help reviewers connect claims to data without contradictory versions.

The scientific value of module 3 should tell a coherent manufacturing story comes from linking knowledge to a controlled decision. The process description, control of materials, critical steps and intermediates, process validation and development sections should agree. Cross-references help reviewers connect claims to data without contradictory versions. Keep this boundary visible: Chemical and biological manufacturing share principles but have different mechanisms and risks.

A strong science note separates observation from interpretation. Audit CTD consistency for module 3 should tell a coherent manufacturing story across process, controls, validation and development sections. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The receipt records target attributes, route, starting-material justification, process map, impurity formation and purge, biological variability, parameters, scale models, design space, analytical methods, controls, validation, CTD locations and lifecycle changes. It makes the strategy auditable.

For a complete q11 receipt follows molecule and impurities, a useful model explains both the expected process and the response to variation. The receipt records target attributes, route, starting-material justification, process map, impurity formation and purge, biological variability, parameters, scale models, design space, analytical methods, controls, validation, CTD locations and lifecycle changes. It makes the strategy auditable. Preserve this guardrail: A supplier’s commercial material is not automatically an acceptable regulatory starting material.

A strong science note separates observation from interpretation. Trace the main molecule and every important impurity through a complete q11 receipt follows molecule and impurities. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter